乌司他丁对肝癌合并门静脉癌栓术后化疗患者肝功能和免疫功能的影响

Effect of ulinastatin on liver and immune function in patients with hepalocellular carcinoma complicated with portal vein tumor thrombus during postoperative chemotherapy

目的观察乌司他丁对肝癌合并门静脉癌栓(HCPVTT)术后化疗患者肝功能和免疫功能的影响。方法 HCPVTT术后化疗患者54例随机分为2组:乌司他丁组(n=28)接受乌司他丁30万单位/d,连续7d;对照组(n=26)注入等量生理盐水。用药后第3、5、7天检测肝功能及NK细胞活性、CD4细胞、CD8细胞和CD4/CD8比值。结果用药后第3天和第7天,乌司他丁组的AST、ALT和TB水平显著低于对照组,而NK细胞活性、CD4细胞和CD4/CD8比值高于对照组,差异有统计学意义(P<0.01)。术后2a无瘤生存率和累计生存率乌司他丁组明显高于对照组(P<0.05)。结论乌司他丁可改善HCPVTT术后化疗患者的肝功能和免疫功能,提高患者的生存率。

Objective To observe the effect of ulinastatin（UTI） on liver and immune function in patients with hepalocellular carcinoma complicated with portal vein tumor thrombus（HCPVTT） during postoperative chemotherapy.Methods Fifty-four HCPVTT patients undergoing postoperative chemotherapy were randomly divided into 2 groups.UTI group（n=28） received UTI at 300 000 U/d for 7 days,while control group（n=26） accepted normal saline.Liver function,NK cell activity,CD4 cells,CD8 cells,and CD4/CD8 ratio were detected on days 3,5,and 7 of treatment.Results Compared with control group,levels of aspartate aminotransforase（AST）,alanine aminotrasferase（ALT） and total brillirubin（TB） decreased,but NK cell activity,CD4 cells,and CD4/CD8 ratio increased in UTI group on days 3 and 7（P〈0.01）.Two year disease-free sand accumulative survival rates in UTI group were significantly higher than those in control group（P〈0.05）.Conclusion UTI can improve the liver and immune function and survival rate in HCPVTT patients undergoing postoperative chemotherapy.